Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions

Executive Summary

The US Treasury released final guidance to eliminate one of the economic motivations behind inversion deals, the threat of which in April derailed the Pfizer/Allergan mega merger. It doesn’t, however, affect other practices as feared.

Advertisement

Related Content

Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
The Fall Of Pfizergan: The Beginning, The End And Everything In Between
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone
US Treasury Hits Back On Inversions; Will Pfizer Fold?
Inversion Crackdown: Does It Spell The End For Pfizer/AstraZeneca?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel